Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Investor Presentation (January 2021)
21 slides from Tarsus Pharmaceuticals's investor presentation, January 2021
Slide 1: Tarsus Corporate Presentation
Tarsus Corporate Presentation January 2021
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and finan
Slide 3: Corporate Highlights
Corporate Highlights Potential for first-ever Pivotal clinical trials FDA-approved in 2021: Saturn-1 therapeutic for Demodex Phase 2b/3 top line blepharitis. Significant data, Saturn-2 Phase 3 market opportunity with no initiation approved therapies Completed five clinical trials, Pipeline with nove
Slide 4: Tarsus Executive Leadership Team
Tarsus Executive Leadership Team Bobby Azamian, M.D., Ph.D., CEO, Co-Founder Leo Greenstein, Chief Financial Officer • Former CEO/CMO Metavention • Former SVP, Finance & Corporate Controller of Spectrum • Extensive investment/entrepreneurial experience with Versant and Pharmaceuticals, Inc. Third Ro
Slide 5: Our Mission
Our Mission To discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye © Tarsus Pharmaceuticals: Confidential & Proprietary 5
Slide 6: Blepharitis is a Large and Underserved Market in Eye Care
Blepharitis is a Large and Underserved Market in Eye Care Epidemiology of Demodex Blepharitis Estimated In-Office Largely ~ 58% of all patients in the eye clinic have collarettes2 Epidemiology Underdiagnosed, but current impression of only 10-15% of blepharitis cases ~25M Education Needed ◦ ~45M uni
Slide 7: Blepharitis has Potential Similarities to Dry Eye Market Years Ago
Blepharitis has Potential Similarities to Dry Eye Market 15 Years Ago Potential Large Latent Demand for a New Therapy • Dry eye is a similar ocular surface disease to Blepharitis, that is likewise treated by ECPs* Dry Eye ICD Diagnoses/Year 7,000,000 • Large untapped patient population that was acti
Slide 8: Half of All Patients Entering Clinic have Collarettes
Half of All Patients Entering Clinic have Collarettes • Since Demodex is newly appreciated as a cause of blepharitis, Tarsus performed the first-ever Demodex blepharitis in-clinic prevalence study • Methods: every consecutive patient seen by the clinic is evaluated for 1. Presence of collarettes (th
Slide 9: Collarettes Are Pathognomonic Sign of Demodex Infestation
Collarettes Are Pathognomonic Sign of Demodex Infestation Collarettes Are Composed of Mite Waste Products and Eggs1 • Regurgitated undigested material combined with epithelial cells, keratin, and mite eggs • Contain digestive enzymes, which cause irritation % of Subjects with Demodex Easily and Rapi
Slide 10: TP-03 is Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis
TP-03 is Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis © Tarsus Pharmaceuticals: Confidential & Proprietary 10
Slide 11: TP-03 is a Novel Therapeutic Designed to Eradicate Demodex Mites
TP-03 is a Novel Therapeutic Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis TP-03 is designed to paralyze the mite nervous system through parasite-specific GABA inhibition Lotilaner • Potent non-competitive antagonist of insect and arachnid GABA-Cl channels • Highly lipophilic mol
Slide 12: TP-03 is a Novel Drug Designed to Treat Demodex Blepharitis
TP-03 is a Novel Drug Designed to Treat Demodex Blepharitis by Eradicating Mites and Collarettes1 Product Form Multi-dose eye drop solution bottle, preserved Targeted Use Treatment of Demodex blepharitis MOA Paralysis and death of Demodex mites Diagnosis Collarettes identified in standard eye examin
Slide 13: Extensive Clinical Trial Program for TP-03
Extensive Clinical Trial Program for TP-03 Trial / Study Design Endpoints Results Achieved Status Ex-vivo mite 100% mites dead within 24 hours PoC: Mercury Ex-vivo mite testing on 80 mites death count (p < 0.001) Collarette Cure Mite Eradication Clinical Trials Rate** Rate 28-day BID dosing, single
Slide 14: Cure of Collarettes with BID Use of TP-03
Cure of Collarettes with BID Use of TP-03 Baseline Post Treatment © Tarsus Pharmaceuticals: Confidential & Proprietary 14
Slide 15: Europa Phase 2b: Results Consistent with Jupiter Trial
Europa Phase 2b: Results Consistent with Jupiter Trial Primary and secondary efficacy endpoints same as Saturn-1 trial Collarette Cure (0-2 collarettes)* Mite Eradication (0 mites) (N=23,20) (N=18,18) (N=15,19) * The primary efficacy endpoint was the proportion of patients experiencing a cure based
Slide 16: TP-03 Phase Clinical Data Show Recurrence Rate of Clinical-Grade Demodex Blepharitis
TP-03 Phase 2 Clinical Data Show Recurrence Rate of Clinical-Grade Demodex Blepharitis Post-Treatment Post treatment data from Mars & Jupiter trials show recurrence of both collarettes & mite density >10 Collarettes on Lid Mite Density of 1.0 or More Post-treatment follow-up Post-treatment follow-up
Slide 17: TP-03 has Significant Market Potential in Demodex Blepharitis
TP-03 has Significant Market Potential in Demodex Blepharitis Opportunity comparable to established ophthalmic therapeutics Large addressable patient population • High prevalence of an estimated 25 million patients and untapped educational opportunity similar to Dry Eye* • 2.1 million current ICD-10
Slide 18: Key Strategies For Potential Commercial Success
Key Strategies For Potential Commercial Success Education on prevalence of Demodex blepharitis • Focus on impact of disease and simplicity of diagnosing via collarettes • Clear patient profiles based on patients that are already in the practice (untreated blepharitis, dry eye, cataracts, contact len
Slide 19: Pipeline with Different Formulations of Novel API
Pipeline with Different Formulations of Novel API Anticipated clinical trial events in our programs in 2021 Anticipated Future Candidate Indication Formulation Preclinical Phase 1 Phase 2 Phase 3 Milestones * Worldwide Rights 2021: Top line data results for Phase 2b/3 Saturn-1 trial Demodex blephari
Slide 20: Tarsus Summary
Tarsus Summary • TP-03 is a novel therapeutic with potential to be the first FDA-approved therapeutic and the standard of care for the treatment of Demodex blepharitis • Clinical efficacy and safety endpoints consistently achieved across multiple Phase 2 studies • Phase 2b/3 Saturn-1 currently enrol
Slide 21: © Tarsus Pharmaceuticals: Confidential & Proprietary
© Tarsus Pharmaceuticals: Confidential & Proprietary 21
Tarsus Pharmaceuticals — Investor Presentation (January 2021) on 6ix